

24. (New) A composition comprising the polypeptide of any one of claims 7 to 11 and 20 and a pharmaceutically acceptable carrier.

REMARKS

Claims 1-6 were pending in the application. Claims 1-6 have been cancelled and claims 7-24 have been added. Accordingly, claims 7-24 will be pending upon entry of the instant amendments presented herein.

Support for the amendments to claims 7-24 may be found in the claims as originally filed and throughout the specification. In particular, support for claim 7 can be found in the specification at least at page 9, lines 13-15; support for claim 8 can be found in the specification at least at page 11, lines 9-12; support for claim 9 can be found in the specification at least at page 3, lines 25-29; support for claim 10 can be found in the specification at least at page 14, lines 24-28; support for claim 11 can be found in the specification at least at page 7, lines 13-16; support for claim 12 can be found in the specification at least at page 15, lines 2-6; support for claim 13 can be found in the specification at least at page 14, line 29 to page 15, line 1; support for claim 14 can be found in the specification at least at page 6, lines 7-16; support for claim 15 can be found in the specification at least at page 6, lines 7-16; support for claim 16 can be found in the specification at least at page 5, line 22 to page 6, line 6; support for claim 17 can be found in the specification at least at page 5, line 26 to page 6, line 2; support for claim 18 can be found in the specification at least at page 6, lines 23-27; support for claim 19 can be found in the specification at least at page 7, lines 9-12; support for claim 20 can be found in the specification at least at page 7, lines 13-16, and at page 15, lines 2-6; support for claim 21 can be found in the specification at least at page 11, lines 9-12, at page 7, lines 13-16, and at page 15, lines 2-6; support for claim 22 can be found in the specification at least at page 6, lines 7-16, at page 7, lines 13-16, and at page 15, lines 2-6; support for claim 23 can be found in the specification at least at page 7, lines 16-17;

and support for claim 24 can be found in the specification at least at page 74, lines 13-15. Amendment or cancellation of the claims should in no way be construed as an acquiescence to any of the Examiner's rejections and was done solely to expedite prosecution. Applicants reserve the right to pursue the claims as originally filed in this or a separate application(s).

**Election / Restriction**

The Office Action has required restriction to one of the following inventions under 35 U.S.C. §§121 and 372:

Group I, claim(s) 1-6, drawn to a protein comprising an amino acid sequence as set forth in SEQ ID NO:1, the DNA encoding this protein, a vector and a host cell.

Group II, claim(s) 1-6, drawn to a protein comprising an amino acid sequence as set forth in SEQ ID NO:2, the DNA encoding this protein, a vector and a host cell.

Group II, claim(s) 1-6, drawn to a protein comprising an amino acid sequence as set forth in SEQ ID NO:3, the DNA encoding this protein, a vector and a host cell.

Group IV, claim(s) 1-6, drawn to a protein comprising an amino acid sequence as set forth in SEQ ID NO:4, the DNA encoding this protein, a vector and a host cell.

Group V, claim(s) 1-6, drawn to a protein comprising an amino acid sequence as set forth in SEQ ID NO:5, the DNA encoding this protein, a vector and a host cell.

Group VI, claim(s) 1-6, drawn to a protein comprising an amino acid sequence as set forth in SEQ ID NO:6, the DNA encoding this protein, a vector and a host cell.

Group VII, claim(s) 1-6, drawn to a protein comprising an amino acid sequence as set forth in SEQ ID NO:7, the DNA encoding this protein, a vector and a host cell.

Group VIII, claim(s) 1-6, drawn to a protein comprising an amino acid sequence as set forth in SEQ ID NO:8, the DNA encoding this protein, a vector and a host cell.

Group IX, claim(s) 1-6, drawn to a protein comprising an amino acid sequence as set forth in SEQ ID NO:9, the DNA encoding this protein, a vector and a host cell.

Group X, claim(s) 1-6, drawn to a protein comprising an amino acid sequence as set forth in SEQ ID NO:10, the DNA encoding this protein, a vector and a host cell.

Group XI, claim(s) 1-6, drawn to a protein comprising an amino acid sequence as set forth in SEQ ID NO:11, the DNA encoding this protein, a vector and a host cell.

Group XII, claim(s) 1-6, drawn to a protein comprising an amino acid sequence as set forth in SEQ ID NO:12, the DNA encoding this protein, a vector and a host cell.

Group XIII, claim(s) 1-6, drawn to a protein comprising an amino acid sequence as set forth in SEQ ID NO:13, the DNA encoding this protein, a vector and a host cell.

Group XIV, claim(s) 1-6, drawn to a protein comprising an amino acid sequence as set forth in SEQ ID NO:14, the DNA encoding this protein, a vector and a host cell.

Group XV, claim(s) 1-6, drawn to a protein comprising an amino acid sequence as set forth in SEQ ID NO:15, the DNA encoding this protein, a vector and a host cell.

Group XVI, claim(s) 1-6, drawn to a protein comprising an amino acid sequence as set forth in SEQ ID NO:16, the DNA encoding this protein, a vector and a host cell.

Group XVII, claim(s) 1-6, drawn to a protein comprising an amino acid sequence as set forth in SEQ ID NO:17, the DNA encoding this protein, a vector and a host cell.

Group XVIII, claim(s) 1-6, drawn to a protein comprising an amino acid sequence as set forth in SEQ ID NO:18, the DNA encoding this protein, a vector and a host cell.

Applicants hereby elect, without traverse, to prosecute the invention of **Group I** (SEQ ID NO:1). Applicants reserve the right to pursue the non-elected subject matter of the nucleic acids or proteins in one or more divisional applications.

### Sequence Rules


At page 4, the Office Action states that the specification is objected to because a computer readable form (CRF) of the sequence listing is absent.

Accordingly, Applicants submit herewith a computer readable form of the Sequence Listing and a hard (paper) copy of the Sequence Listing, both of which include all of the sequences that are present in the application. The content of the hard copy of the substitute Sequence Listing and the computer readable form of the substitute Sequence Listing are the same and include no new matter. Accordingly, Applicants respectfully request that the objections pertaining to the sequence listing be withdrawn.

### Conclusion

If a telephone conversation with Applicants' Attorney would help expedite the prosecution of the above-identified application, the Examiner is urged to call Applicants' Attorney at (617) 227-7400.

Respectfully submitted,  
LAHIVE & COCKFIELD, LLP



Cynthia L. Kanik, Esq.  
Registration No. 37,320  
Attorney for Applicants

28 State Street  
Boston, MA 02109  
(617) 227-7400

Dated: June 28, 2001